Deng Jiu, Zhang Xiuli, Chen Zongzheng, Luo Yong, Lu Yao, Liu Tingjiao, Wu Zhengzhi, Jin Yu, Zhao Weijie, Lin Bingcheng
State Key Laboratory of Fine Chemicals, Department of Chemical Engineering & School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian 116024, China.
College of Pharmaceutical Science, Soochow University, Soochow 215123, China.
Biomicrofluidics. 2019 Mar 7;13(2):024101. doi: 10.1063/1.5070088. eCollection 2019 Mar.
The poor metabolic ability of cell lines fails to meet the requirements of an model for drug interaction testing which is crucial for the development or clinical application of drugs. Herein, we describe a liver sinusoid-on-a-chip device composed of four kinds of transformed cell lines (HepG2 cells, LX-2 cells, EAhy926 cells, and U937 cells) that were ordered in a physiological distribution with artificial liver blood flow and biliary efflux flowing in the opposite direction. This microfluidic device applied three-dimensional culturing of HepG2 cells with high density (10 ml), forming a tightly connected monolayer of EAhy926 cells and achieving the active transport of drugs in HepG2 cells. Results showed that the device maintained synthetic and secretory functions, preserved cytochrome P450 1A1/2 and uridine diphosphate glucuronyltransferase enzymatic activities, as well as sensitivity of drug metabolism. The cell lines derived device enables the investigation of a drug-drug interaction study. We used it to test the hepatotoxicity of acetaminophen and the following combinations: "acetaminophen + rifampicin," "acetaminophen + omeprazole," and "acetaminophen + ciprofloxacin." The variations in hepatotoxicity of the combinations compared to acetaminophen alone, which is not found in a 96-well plate model, in the device were -17.15%, 14.88%, and -19.74%. In addition, this result was similar to the one tested by the classical primary hepatocyte plate model (-13.22%, 13.51%, and -15.81%). Thus, this cell lines derived liver model provides an alternative to investigate drug hepatotoxicity, drug-drug interaction.
细胞系较差的代谢能力无法满足药物相互作用测试模型的要求,而该模型对于药物开发或临床应用至关重要。在此,我们描述了一种芯片上的肝窦状隙装置,它由四种转化细胞系(HepG2细胞、LX-2细胞、EAhy926细胞和U937细胞)组成,这些细胞系按生理分布排列,人工肝血流和胆汁外排方向相反。这种微流控装置对高密度(10毫升)的HepG2细胞进行三维培养,形成紧密连接的EAhy926细胞单层,并实现药物在HepG2细胞中的主动转运。结果表明,该装置保持了合成和分泌功能,保留了细胞色素P450 1A1/2和尿苷二磷酸葡萄糖醛酸转移酶的酶活性以及药物代谢敏感性。源自细胞系的该装置能够进行药物-药物相互作用研究。我们用它测试了对乙酰氨基酚及其以下组合的肝毒性:“对乙酰氨基酚+利福平”、“对乙酰氨基酚+奥美拉唑”和“对乙酰氨基酚+环丙沙星”。与单独使用对乙酰氨基酚相比,该装置中组合的肝毒性变化(在96孔板模型中未发现)分别为-17.15%、14.88%和-19.74%。此外,该结果与经典原代肝细胞板模型测试的结果相似(-13.22%、13.51%和-15.81%)。因此,这种源自细胞系的肝脏模型为研究药物肝毒性、药物-药物相互作用提供了一种替代方法。